Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03537547 · ClinicalTrials.gov registry record · Phase 4
Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
A Phase 4 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03537547: Clinical Trial Phase 4 study, sponsored by Washington University School of Medicine.
NCT03537547 is a Phase 4 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03537547, a Phase 4 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study aims to determine whether the GeneSight Psychotropic test can result in better treatment outcomes for patients with treatment-naive major depressive disorder
Primary Outcome
17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity. Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.
Interventions
- OTHER GeneSight Psychotropic test
- DRUG FDA-approved antidepressant or antipsychotic treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-05-04 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 4 |
Why NCT03537547 stopped before completion
NCT03537547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which GeneSight Psychotropic test is the first listed.
NCT03537547 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03537547 about?
NCT03537547 is a clinical study titled "Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder". This study aims to determine whether the GeneSight Psychotropic test can result in better treatment outcomes for patients with treatment-naive major depressive disorder
What is the current status of trial NCT03537547?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-05-04. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT03537547?
The interventions under investigation include: GeneSight Psychotropic test (OTHER), FDA-approved antidepressant or antipsychotic treatment (DRUG).
Who is sponsoring clinical trial NCT03537547?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03537547's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI